Nohla Therapeutics attracts $43.5 mln Series A

Nohla Therapeutics Inc, a developer of universal donor cellular therapies for patients with hematological disorders and cancers, has secured $43.5 million in Series A financing. ARCH Venture Partners led the round with participation from 5AM Ventures and Jagen Group. In addition to the funding, Dr. Steven Gillis, a managing director at ARCH Venture Partners, and Dr. Brian Daniels, a venture partner at 5AM Ventures, have been added to Nohla's board of directors as chairman and director, respectively.

North AmericaUSBriefs